GlassScriptPhysician profile
Javier E Sanchez Martinez
NPI 1245763440
$11,215.97
in general payments reported to CMS, 2019-2025
20 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $3,335 · 2023: $5,664 · 2024: $1,126 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,537 · Grant: $1,875 · Travel and Lodging: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,537.33 |
| Grant | $1,875.00 |
| Travel and Lodging | $1,326.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,943.82 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $2,777.20 | 2022-2025 | Vercise, Intracept |
| Relievant Medsystems, INC. | $1,152.91 | 2023 | Intracept |
| Spr Therapeutics, INC | $369.73 | 2023-2025 | Sprint Pns System |
| Tersera Therapeutics LLC | $313.95 | 2023-2025 | Prialt |
| Nalu Medical, INC. | $311.23 | 2022-2024 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $262.91 | 2023-2024 | Mild Device Kit |
| Nevro Corp. | $213.20 | 2022-2023 | Senza |
| Si-Bone, INC. | $154.18 | 2025 | |
| Collegium Pharmaceutical, INC. | $111.66 | 2022-2023 | Belbuca |
| Saluda Medical Americas, INC. | $97.87 | 2024-2025 | Evoke |
| Mml US, INC. | $94.49 | 2024 | Reactiv8 |
| Captiva Spine INC | $62.26 | 2023 | Caplox II |
| Spinal Simplicity, LLC | $49.32 | 2025 | Ha Minuteman G3-R |
| Southern Edge Orthopaedics, INC. | $47.04 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.77 | 2024 | Eterna, Proclaim |
| Depuy Synthes Sales INC. | $21.61 | 2023 | Orthovisc |
| Biotronik Nro, INC. | $20.87 | 2024 | Prospera |
| Kowa Pharmaceuticals America, INC. | $20.26 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.61 | 2023 | Exparel, Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Sanchez Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.